Revenue composition centered on direct sales
First written in FY2022-Q1. 7 of 15 entries say "Reframed", first in FY2022. Latest entry: 2026-09-11.
Waqoo moved to the "Worse" side of this theme in 2026.
The whole theme swung hardest in 2026: 2 of 13 companies on the "Worse" side.
3 other companies' latest entry also says "Reframed".
- FY2025AdvancedAnnual report
「Direct sales ¥948.132 million Blood processing ¥364.405 million Raw-material sales ¥633.305 million Other ¥15.058 million Revenue from contracts with customers ¥1,960.902 million」
D2C revenue remained centered on direct sales, while Medical Support revenue centered on blood processing and raw-material sales. Raw-material sales increased to ¥633.305 million from ¥347.674 million. - FY2025-H1RestatedAnnual report
「Direct sales ¥500.201 million Blood processing ¥153.075 million Raw-material sales ¥176.828 million Other ¥4.749 million Revenue from contracts with customers ¥834.854 million」
The interim consolidated period continued to show direct sales in D2C and blood processing and raw-material sales in Medical Support. - FY2024ReframedAnnual report
「Direct sales ¥1,285.188 million Blood processing ¥279.400 million Raw-material sales ¥347.674 million Other ¥31.141 million Revenue from contracts with customers ¥1,943.404 million」
In addition to direct sales, blood processing and raw-material sales became the main Medical Support revenue categories. - FY2024-Q2ReframedAnnual report
「Direct sales ¥689.623 million Blood processing ¥131.339 million Other ¥113.372 million Revenue from contracts with customers ¥934.335 million」
Direct sales remained the largest revenue category, while blood-processing revenue of ¥131.339 million was added after Cellpro Japan was consolidated. - FY2024-Q1RestatedAnnual report
「Direct sales ¥360.364 million Other ¥21.145 million Revenue from contracts with customers ¥381.509 million Medical Support business ¥64.368 million」
The first quarter continued to show direct-sales-centered D2C revenue alongside Medical Support revenue. - FY2023ReframedAnnual report
「Direct sales ¥1,517.043 million Other ¥42.766 million Revenue from contracts with customers ¥1,559.809 million Medical Support business ¥166.504 million」
Direct sales continued to dominate D2C revenue, while Medical Support revenue was disclosed as ¥166.504 million in other revenue. - FY2023-Q2RestatedAnnual report
「Direct sales ¥829.864 million Other ¥29.816 million Revenue from contracts with customers ¥859.681 million」
Direct sales accounted for most D2C revenue; including ¥40.978 million of other Medical Support revenue, total revenue from contracts with customers was ¥900.659 million. - FY2023-Q1RestatedAnnual report
「Direct sales ¥456.904 million Other ¥32.977 million Revenue from contracts with customers ¥489.882 million」
First-quarter revenue from contracts with customers comprised ¥456.904 million from direct sales and ¥32.977 million from other sources. - FY2022ReframedAnnual report
「Direct sales ¥2,414.423 million Advertising production and ad operations ¥200.008 million Other ¥116.944 million Revenue from contracts with customers ¥2,731.376 million」
The direct-sales-centered revenue mix added ¥200.008 million from advertising production and ad operations in the Medical Support business. - FY2022-Q3RestatedAnnual report
「Direct sales ¥1,910.565 million Other ¥138.016 million Revenue from contracts with customers ¥2,048.581 million」
Direct sales accounted for most third-quarter cumulative-period revenue, while other revenue included sales from the new Medical Support business. - FY2022-Q2RestatedAnnual report
「Direct sales ¥1,346.330 million Other ¥71.927 million Revenue from contracts with customers ¥1,418.257 million」
Second-quarter cumulative-period revenue comprised ¥1,346.330 million from direct sales and ¥71.927 million from other sources, with direct sales continuing to account for most revenue. - FY2022-Q1First statedAnnual report
「Direct sales ¥740.965 million Other ¥66.080 million Revenue from contracts with customers ¥807.046 million」
Revenue from contracts with customers in the first-quarter cumulative period comprised ¥740.965 million from direct sales and ¥66.080 million from other sources.